Brief: Soligenix Announces Agreement On Design Of Second Confirmatory Placebo-Controlled Trial For HyBryte With European Medicines Agency

Soligenix

03/04/2024 12:38

April 3 (Reuters) - Soligenix Inc  SNGX.O :
    * SOLIGENIX ANNOUNCES AGREEMENT ON THE DESIGN OF A SECOND
CONFIRMATORY PLACEBO-CONTROLLED TRIAL FOR HYBRYTE™ WITH THE
EUROPEAN MEDICINES AGENCY
    * SOLIGENIX ANNOUNCES AGREEMENT ON THE DESIGN OF A SECOND
CONFIRMATORY PLACEBO-CONTROLLED TRIAL FOR HYBRYTE™ WITH THE
EUROPEAN MEDICINES AGENCY
    * SOLIGENIX INC: CONFIRMATORY 18-WEEK STUDY IS EXPECTED TO
ENROLL
APPROXIMATELY 80 PATIENTS IN UNITED STATES AND EUROPE
    * SOLIGENIX INC: CONFIRMATORY 18-WEEK STUDY TARGETED TO
BEGIN
PATIENT ENROLLMENT BY END OF 2024 WITH TOP-LINE RESULTS
ANTICIPATED IN SECOND HALF OF 2026

Source text for Eikon:  ID:nPn879wj8a 
Further company coverage:  SNGX.O 

 ((Reuters.Briefs@thomsonreuters.com;))